CF3CN has shown efficacy in promoting TrkB activation, inhibiting δ-secretase, and increasing TH-positive dopaminergic neurons in MPTP-induced human SNCA transgenic PD mice [109]. Here, NTRK2 is linked to Parkinson disease.